ASCLETIS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 HKD | -1.47% |
|
+4.69% | -8.22% |
| 03/04 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| 03/04 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
| Sales 2023 | 56.6M 7.81M 61.14M 651M | Sales 2024 * | - | Capitalization | 1.26B 173M 1.36B 14.46B |
|---|---|---|---|---|---|
| Net income 2023 | -145M -20.01M -157M -1.67B | Net income 2024 * | -219M -30.22M -237M -2.52B | EV / Sales 2023 | -15.6 x |
| Net cash position 2023 | 2.27B 313M 2.45B 26.08B | Net cash position 2024 * | 2B 276M 2.16B 23.02B | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-9.85
x | P/E ratio 2024 * |
-6.12
x | Employees | 219 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 28.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.47% | ||
| 1 week | +4.69% | ||
| Current month | -6.29% | ||
| 1 month | -4.96% | ||
| 3 months | -21.18% | ||
| 6 months | -25.97% | ||
| Current year | -8.22% |
1 week
1.23
1.36
1 month
1.211.43
Current year
1.211.93
1 year
1.212.87
3 years
1.217.26
5 years
1.217.26
10 years
1.2114.90
| Managers | Title | Age | Since |
|---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Yan Yuemei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Handan He
CTO | Chief Tech/Sci/R&D Officer | - | 07/19/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Jiong Gu
BRD | Director/Board Member | 51 | 01/18/01 |
| Chief Operating Officer | 50 | 13/19/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.78% | 4 M€ | -27.92% | ||
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.34 | -1.47% | 1,498,000 |
| 25/24/25 | 1.36 | +3.82% | 456,000 |
| 24/24/24 | 1.31 | +3.15% | 408,000 |
| 23/24/23 | 1.27 | 0.00% | 365,000 |
| 22/24/22 | 1.27 | -0.78% | 307,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:38 pm IST
More quotes
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
Sector
Pharmaceuticals
Calendar
19/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.24
CNY
Average target price
2.752
CNY
Spread / Average Target
+121.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.22% | 173M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 1672 Stock
